HY-90006-5-Fluorouracil试剂-杭州昊鑫生物科技股份有限公司手机版

详细介绍

5-Fluorouracil试剂简介

5-Fluorouracil (5-FU) 是一种uracil的类似物 (nucleoside antimetabolite/analog)，是一种有效的抗肿瘤药。5-Fluorouracil 通过抑制胸苷酸合成酶影响嘧啶的合成，从而耗尽细胞内dTTP 池。5-Fluorouracil 诱导细胞凋亡 (apoptosis)，可用作化学敏化剂。5-Fluorouracil 还可抑制 HIV 病毒。5-Fluorouracil (5-FU) 可破坏外泌体特异性的 rRNA。

5-Fluorouracil试剂生物活性

5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer^[1]^[2]. 5-Fluorouracil also inhibits HIV^[3].

IC₅₀ & Target^[1]^[6]

HIV

体外研究
(In Vitro)

5-Fluorouracil (5-Fu) and NSC 123127 (Dox) show synergistic anticancer efficacy. The IC₅₀ value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively^[1]. In 5-fluorouracil (5-FU) and CDDP treated NFBD1-inhibited NPC cells, the NFBD1 expression in NPC CNE1 cell lines is depleted using lentivirus-mediated short hairpin RNA, and the sensitivity of these cells is elevated. NFBD1 knockdown leads to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

130.08

性状

Solid

Formula

C₄H₃FN₂O₂

CAS 号

51-21-8

中文名称

5-氟脲嘧啶；双喃呋啶

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 50 mg/mL (384.38 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	7.6876 mL	38.4379 mL	76.8758 mL
5 mM	1.5375 mL	7.6876 mL	15.3752 mL
10 mM	0.7688 mL	3.8438 mL	7.6876 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution
4.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline
Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution
5.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution
6.

请依序添加每种溶剂： 5% DMSO 95% saline
Solubility: 2.5 mg/mL (19.22 mM); Clear solution; Need ultrasonic

10 mM * 1 mL in DMSO	500元	10000 可售
200 mg	350元	10000 可售
1 g	450元	10000 可售
5 g	840元	10000 可售

产品简介

详细介绍